[ad_1]
The Data and Safety Oversight Board “expressed concern that AstraZeneca may have included outdated information from those tests, which may not provide a complete picture of efficacy data,” the US National Institute of Allergy and Communicable Diseases said. In a statement.
Earlier Monday, AstraZeneca announced that its vaccine provides reliable protection against coronavirus infection in adults of all ages. These findings, based on the results of a recent study in the US, appeared to be important in restoring global confidence in the drug and bringing its registration closer to the US.
After conducting studies involving 30 thousand. people, 79% of those vaccinated, including the elderly. effectively prevent the development of coronavirus infection symptoms. None of the vaccine volunteers were seriously ill or hospitalized, compared to five in the placebo control group at the time.
AstraZeneca also said that the study’s independent safety supervisors found no serious side effects, nor was there an increased risk of blood clots. Recent fears of a rare blood clotting disorder in Europe last week led a number of countries to temporarily suspend vaccination with AstraZeneca.
